Wei Jie Guan;Wen Hua Liang;Yi Zhao;Heng Rui Liang;Zi Sheng Chen;Yi Min Li;Xiao Qing Liu;Ru Chong Chen;Chun Li Tang;Tao Wang;Chun Quan Ou;Li Li;Ping Yan Chen;Ling Sang;Wei Wang;Jian Fu Li;Cai Chen Li;Li Min Ou;Bo Cheng;Shan Xiong;Zheng Yi Ni;Jie Xiang;豫 胡;Lei Liu;Hong Shan;Chun Liang Lei;Yi Xiang Peng;Li Wei;Yong Liu;Ya Hua Hu;Peng Peng;Jian Ming Wang;Ji Yang Liu;Zhong Chen;Gang Li;Zhi Jian Zheng;Shao Qin Qiu;Jie Luo;Chang Jiang Ye;Shao Yong Zhu;Lin Ling Cheng;Feng Ye;Shi Yue Li;Jin Ping Zheng;Nuo Fu Zhang;南山 钟;Jian Xing He
Guangzhou Medical College;Southern Medical University;Wuhan Jin-Yin-Tan Hospital;Huazhong University of Science and Technology;Shenzhen Third People's Hospital;Sun Yat-Sen University;University of California at San Diego;Public Health Clinical Center of Chengdu;Hubei Polytechnic University;Wuhan Pulmonary Hospital;Wuhan University of Science and Technology;First Hospital of Changsha;The Third People's Hospital of Hainan Province;Third People's Hospital of Huanggang;Wenzhou Medical University;Third People's Hospital of Yichang;Hubei University of Medicine;Xiantao First People's Hospital
期 刊：European Respiratory Journal
Background: The coronavirus disease 2019 (Covid-19) outbreak is evolving rapidly worldwide. Objective: To evaluate the risk of serious adverse outcomes in patients with coronavirus disease 2019 (Covid-19) by stratifying the comorbidity status. Methods: We analyzed the data from 1,590 laboratory-confirmed hospitalized patients 575 hospitals in 31 province/autonomous regions/provincial municipalities across mainland China between December 11th, 2019 and January 31st, 2020. We analyze the composite endpoints, which consisted of admission to intensive care unit, or invasive ventilation, or death. The risk of reaching to the composite endpoints was compared according to the presence and number of comorbidities. Results: The mean age was 48.9 years. 686 patients (42.7%) were females. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD [hazards ratio (HR) 2.681, 95% confidence interval (95%CI) 1.424-5.048], diabetes (HR 1.59, 95%CI 1.03-2.45), hypertension (HR 1.58, 95%CI 1.07-2.32) and malignancy (HR 3.50, 95%CI 1.60-7.64) were risk factors of reaching to the composite endpoints. The HR was 1.79 (95%CI 1.16-2.77) among patients with at least one comorbidity and 2.59 (95%CI 1.61-4.17) among patients with two or more comorbidities. Conclusion: Among laboratory-confirmed cases of Covid-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.